Genentech to present new data from neuroscience portfolio at ECTRIMS
Category: #health  By Pankaj Singh  Date: 2019-09-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech to present new data from neuroscience portfolio at ECTRIMS
  • The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.
     
  • The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neuromyelitis Optica Spectrum Disorder treatment.

Genentech, a biotechnology company and a subsidiary of Roche Group, reportedly announced that pivotal data from its neuroscience portfolio would be showcased in the 35th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) between September 11 and 13 in Stockholm.

The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab for the treatment of Neuromyelitis Optica Spectrum Disorder, and latest Multiple Sclerosis research, which offers insights into progression of the disease, it comprises information from Ocrevus ® study that improve the understanding about Neurofilament Light Chain levels as a capable biomarker for forecasting disability results.

Furthermore, longer-term data of over six years to be proposed continue to show constant efficacy and safety outcomes for patients who took Ocrevus treatment previously.

Chief Medical Officer and Global Product Development Head at Genentech, Sandra Horning, M.D., stated that nervous system disorders are very difficult and complex to treat, and the company has grown its commitment towards neuroscience to enhance scientific understanding and care for conditions like Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.

Horning added that data being shown at ECTRIMS also contains positive Phase III outcomes for satralizumab taken as a monotherapy, a novel approach for the treatment of Neuromyelitis Optica Spectrum Disorder, as well as novel insights utilizing biomarkers to recognize disease progression happening in multiple sclerosis. 

Horning also stated that similar to the company’s approach with Ocrevus regarding Multiple Sclerosis, aiming at B cells as the crucial driver of disease, the company aims to provide satralizumab as an effective Neuromyelitis Optica Spectrum Disorder treatment option.

 

Source credit:  https://www.gene.com/media/press-releases/14805/2019-09-03/genentech-to-present-pivotal-data-for-sa

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Rogers Communications launches 5G network services across Canada
Rogers Communications launches 5G network services across Canada
By Pankaj Singh

  The network will first be implemented in Toronto, Vancouver, Montreal and Ottawa Rogers has collaborated with Ericsson to provide the required technology to develop the network Rogers Communications – a Toronto based telecommunicat...

Amazon orders StreetScooter electric vans to fuel carbon neutral goals
Amazon orders StreetScooter electric vans to fuel carbon neutral goals
By Pankaj Singh

Amazon has ordered about 40 electric vans from Deutsche Post’s StreetScooter in Munich   The Work L delivery van shall be debuted in two of the urban U.S. markets from spring 2020 Amazon.com has reportedly ordered about 40 electric v...

Oyster Point Pharma attains primary endpoint in MYSTIC trial
Oyster Point Pharma attains primary endpoint in MYSTIC trial
By Pankaj Singh

A clinical-stage biopharmaceutical company, Oyster Point Pharma, Inc. recently announced positive results from its Phase 2 MYSTIC clinical study for Dry Eye Disease. For the record, Oyster Point Pharma is focused upon discovering, developing, and co...